uploads/2018/03/dna-163466_1280.jpg

How Analysts View Agios Pharmaceuticals and Peers in March 2018

By

Updated

Company overview

Agios Pharmaceuticals (AGIO) is a biopharmaceutical company with therapeutic focus areas of cancer and rare genetic diseases. The company’s first commercial product is Idhifa, which received FDA approval in August 2017. Idhifa has been approved for the treatment of adult patients with R/R AML and IDH2 mutations and is the first and only FDA-approved therapy for this indication.

Article continues below advertisement

Analysts’ recommendations

Of the nine analysts covering Agios Pharmaceuticals (AGIO) in March 2018, one analyst gave it a “strong buy” rating, six analysts gave it a “buy” rating, and two analysts gave it a “hold” rating. The mean rating for the stock is ~2.1 with a target price of $86.13.

Peer ratings

Of the nine analysts covering Akebia Therapeutics (AKBA) in March 2018, one analyst gave the stock a “strong buy” rating, seven analysts gave it a “buy” rating, and one analyst gave it a “hold” rating. The mean rating for the stock is 2.0 with a target price of $22.11.

Of the 22 analysts covering Eli Lilly & Co. (LLY) in March 2018, 13 analysts gave the stock a “buy” or a higher rating. Seven analysts gave it a “hold” rating, and two analysts gave the stock a “sell” rating. The mean rating for the stock is 2.2 with a target price of $91.29.

Of the eight analysts covering Novavax (NVAX) in March 2018, two analysts gave the stock a “strong buy” rating, and one analyst gave it a “buy” rating. Four analysts gave Novavax a “hold” rating, and one analyst gave it a “sell” rating. The mean rating for the stock is 2.5 with a target price of $3.83.

In the next part of this series, we’ll take a look at Agios Pharmaceuticals’ development programs.

Advertisement

More From Market Realist